Remember meForgot password?
    Log in with Twitter
Press Release

Histone Deacetylase Inhibitors Market to Grow Promisingly Owing to Rising Prevalence of Chronic Diseases

Histone Deacetylase Inhibitors Market to Reach Remarkable Heights on Account of Increasing Demand for Cancer Therapeutics

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 06/25/2019 -- The rising prevalence of cancer all around the globe is augmenting the global histone deacetylase inhibitors market, says Fortune Business Insights in their recent study. The study is titled, "Histone Deacetylase Inhibitors Market Size, Share and Global Trend by Class (Class I HDACs, Class II HDACS, Class III HDACs, Class IV HDACs), Application (Oncology, Neurology), End User (Hospitals, Academic & research institutes, Pharmaceutical companies) and Geography Forecast till 2026,", and it states the rise in demand for treating cancer has brought lucrative growth opportunities for the market globally.

Sample PDF Brochure at

Some of the major companies that are present in the Global Histone Deacetylase Inhibitors Market are;

- Merck KGaA
- Medivir AB
- Cetya Therapeutics
- BioVision Inc.
- R&D Systems, Inc.
- Mirati Therapeutics
- Abcam plc.
- TCI Chemicals (India) Pvt. Ltd.
- InvivoGen and other players.

Fortune Business Insights foresees the cancer segment to account for the largest share in the market, due to its rising prevalence. Increasing expenditure on healthcare especially for the treatment of cancer is helping the cancer segment lead the market.

Cancer Prevalence to Aid in Favor of Market

Various factors are responsible for the growth of the global histone deacetylase market including the increasing number of cancer cases as mentioned above. Other factors include the presence of skilled professionals in developed regions, increasing number of neurological disorders and tumor cases, and supportive reimbursement policies by governments. As per the World Health Organization, the second major cause of death in the world is cancer. In 2018, cancer was the cause of death in an estimated 9.6 million people around the world.

On the flip side, the market may face challenges in terms of inadequate reimbursement policies and uncertainty issues related to histone deacetylase inhibitors. However, the rise in awareness about various chronic diseases and the availability of diagnostics for treating such diseases will help the market gain momentum in the coming years.

Market to Gain Impetus from Government Reimbursement Policies

From a geographical standpoint, the global histone deacetylase inhibitors market is dominated by North America on account of the rising prevalence of neurological disorders and cancer. The American Cancer Society states an estimated 12% of women in the U.S. develop breast cancer during their lifetime. The report also stated an estimate of 2300 men in the U.S. to be diagnosed with breast cancer. This, coupled with, the high acceptance of histone deacetylase inhibitors in developed nations of Canada and the U.S. is likely to help North America continue to dominate the market during the forecast period too.

On the other hand, Europe and the Asia Pacific regions are anticipated to grow at faster rates owing to the increasing number of neurological disorder cases and the improving healthcare facilities in the respective regions. Besides this, the surge in demand for advanced treatment by a large number of patients is a major factor propelling growth in both regions.

Major vendors in the global histone deacetylase inhibitors market are focusing on strategies such as company collaborations, new product launches, mergers, and acquisitions. They are also investing huge sums in research and development for creating innovative drugs. To cite an instance, interim data of Phase 2 study evaluating pracinostat was announced in December 2018, by Helsinn Healthcare S.A. Pracinostat is a histone deacetylase inhibitor that combines with azacitidine for treating patients suffering from a higher stage of Myelodysplastic Syndrome (MDS) or IPSS-R high. Some of the players operating in the global histone deacetylase inhibitors market are Abcam plc., Cetya Therapeutics, R&D Systems, Inc., Mirati Therapeutics, TCI Chemicals (India) Pvt. Ltd., InvivoGen, BioVision Inc., Medivir AB, and Merck KGaA.

Browse Complete Report Details at

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

For more information on this press release visit:

Media Relations Contact

Ashwin Arora
Fortune Business Insights
Telephone: 1-424-253-0390
Email: Click to Email Ashwin Arora

Latest News
Top News